Skip to main content

Conor McNamara

Stock Analyst at RBC Capital

Total Price Targets
4
Stocks Covered
3
Sectors
Healthcare
Most Recent
Sep 2, 2025

Notable Calls (Last 12 Months)

Most Bullish

  • NTRA+58.3%
    Natera, Inc.
    $268.00 targetSep 2, 2025
  • TECH+36.7%
    Bio-Techne Corporation
    $73.00 targetSep 2, 2025
  • TMO+15.1%
    Thermo Fisher Scientific Inc.
    $561.00 targetSep 2, 2025

Most Bearish

  • TMO+15.1%
    Thermo Fisher Scientific Inc.
    $561.00 targetSep 2, 2025
  • TECH+36.7%
    Bio-Techne Corporation
    $73.00 targetSep 2, 2025
  • NTRA+58.3%
    Natera, Inc.
    $268.00 targetSep 2, 2025

Stocks Covered by Conor McNamara

SymbolCompanyLatest TargetCurrent PriceUpside# TargetsLast Updated
NTRANatera, Inc.$268.00$207.56+29.1%1Sep 2, 2025
TECHBio-Techne Corporation$73.00$55.17+32.3%1Sep 2, 2025
TMOThermo Fisher Scientific Inc.$561.00$469.31+19.5%2Sep 2, 2025

Recent Activity

  • Sep 2, 2025— Set$268.00price target onNTRA(Natera, Inc.)
  • Sep 2, 2025— Set$73.00price target onTECH(Bio-Techne Corporation)
  • Sep 2, 2025— Set$561.00price target onTMO(Thermo Fisher Scientific Inc.)
  • Jan 31, 2025— Set$693.00price target onTMO(Thermo Fisher Scientific Inc.)

Frequently Asked Questions

Who is Conor McNamara?

Conor McNamara is a stock analyst at RBC Capital covering 3 stocks primarily in Healthcare. They have issued 4 price targets since Jan 31, 2025.

What stocks does Conor McNamara cover?

Conor McNamara currently covers 3 stocks, including TMO, NTRA, TECH.

What is Conor McNamara's latest price target?

Conor McNamara's most recent price target was $268.00 on NTRA (Natera, Inc.), set on Sep 2, 2025.

What is Conor McNamara's highest price target?

Conor McNamara's highest issued price target is $693.00 on TMO, set on Jan 31, 2025.

More Analysts at RBC Capital

Matthew Hedberg
RBC Capital
Targets112
Stocks36
Arun Viswanathan
RBC Capital
Targets95
Stocks26
Brad Erickson
RBC Capital
Targets91
Stocks25
Rishi Jaluria
RBC Capital
Targets87
Stocks26

Coverage based on publicly published price targets. Not investment advice.